JNJ-55511118 是一种具有口服生物利用度和血脑屏障通透性的选择性 TARP γ-8 结合型 AMPA 受体调节剂(Ki 为 26 nM),可减少雄性小鼠对甜味酒精的自主摄取,在啮齿动物模型中可抑制海马神经传递、降低特定脑电图频段、诱导短暂性运动过度、损伤学习记忆能力并发挥抗惊厥作用,可用于酒精使用障碍和癫痫发作的相关研究。
产品编号: MS-D59749 纯度: 99.85% CAS No.: 2036081-86-2 分子式: C14H8ClF3N2O2 分子量: 328.67
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

JNJ-55511118 是一种具有口服生物利用度和血脑屏障通透性的选择性 TARP γ-8 结合型 AMPA 受体调节剂(Ki 为 26 nM),可减少雄性小鼠对甜味酒精的自主摄取,在啮齿动物模型中可抑制海马神经传递、降低特定脑电图频段、诱导短暂性运动过度、损伤学习记忆能力并发挥抗惊厥作用,可用于酒精使用障碍和癫痫发作的相关研究。

生物实验数据

生物活性 JNJ-55511118 is an orally bioavailable and blood-brain barrier-penetrant selective TARP γ-8-bound AMPA receptor modulator with a Ki of 26 nM that reduces voluntary sweetened alcohol intake in male mice, inhibits hippocampal neurotransmission, reduces specific EEG frequency bands, induces transient hyperlocomotion, impairs learning and memory, and exerts anticonvulsant effects in rodent models, and can be used for research on alcohol use disorder and seizures.
IC50 & Target

AMPA Receptor

26 nM (Ki)

体外研究
(In Vitro)

JNJ-55511118 是一种强效、选择性的含 TARP-γ8 的 AMPA 受体负调节剂,在人、大鼠、小鼠、猴和犬的 GluA-γ8 组合中,其平均 pIC50 值为 7.42 至 8.33,且对不含 γ8 的 TARP 型或无 TARP 型 AMPA 受体无活性。
JNJ-55511118 (1 μM; 50-60 s) 通过加速脱敏和失活过程,抑制异源表达的含 TARP-γ8 的 AMPA 受体中谷氨酸诱发电流。
JNJ-55511118 对人源 5-HT2B 受体具有弱拮抗活性 (IC50 = 6 μM)。

体内研究
(In Vivo)

JNJ-55511118 (0-10 mg/kg;p.o.;单次) 可显著降低雄性 C57BL/6J 小鼠甜酒自主摄取的多项指标,不会降低雌性 C57BL/6J 小鼠的甜酒自主饮用相关参数,但 10 mg/kg 剂量会通过增加无效杆的应答次数改变杆辨别行为。
JNJ-55511118 (i.v./p.o.,0-10 mg/kg,单次) 可在麻醉大鼠中抑制海马 CA1 区群体锋电位,其静脉注射 ED50 为 0.4 mg/kg,可在自由活动大鼠中呈剂量依赖性降低多个频段的皮层脑电图功率,10 mg/kg 灌胃剂量下会出现短暂性运动过度。
JNJ-55511118 (p.o.;单次,0-40 mg/kg) 可在角膜、杏仁核点燃小鼠模型中产生强效、近乎完全的癫痫发作保护作用,其经口给药的 ED50 为 3.7 mg/kg,可在 Mus musculus 的 6 Hz 精神运动性癫痫模型中产生呈部分剂量依赖性的癫痫保护作用,其 ED50 值分别为 18.3 mg/kg p.o. (32 mA) 和 6.5 mg/kg p.o. (44 mA),提高小鼠对 PTZ 的惊厥阈值。

Animal Model: C57BL/6J (male/female)
Dosage: 1 mg/kg; 10 mg/kg
Administration: p.o.; single dose
Result: Reduced alcohol-reinforced response rate from 10 to 60 minutes post-administration compared to vehicle.
Reduced total active lever presses, number of alcohol reinforcers earned, and alcohol intake (g/kg/1h) compared to vehicle.
Decreased percentage of responses on the active lever from 92.4 (vehicle) to 76.5 ± 5 (1 mg/kg) and 75.7 (10 mg/kg).
Increased inactive lever responding at 10 mg/kg dose.
Showed no effect on open-field ambulatory distance in alcohol-exposed or sucrose-exposed mice at 1 mg/kg dose.
Showed no effect on sucrose-only self-administration parameters.
Showed no effect on alcohol-reinforced response rate, total active lever presses, number of alcohol reinforcers earned, or alcohol intake (g/kg/1h).
Reduced percentage of responses on the active lever from 92 (vehicle) to 79.9 at 10 mg/kg dose.
Increased inactive lever responding at 10 mg/kg dose.
Showed no effect on sucrose-only self-administration parameters.
Animal Model: Sprague-Dawley (male, 300-450 grams)
Dosage: 0, 0.25, 0.5, 1, 2, 3, 4, 8, 10 mg/kg
Administration: i.v./p.o., single dose
Result: Caused rapid, dose-dependent inhibition of evoked population spike amplitude.
Fitted an ED50 of 0.4 mg/kg i.v.
for inhibition.
Achieved near-complete inhibition of population spikes at 8 mg/kg.
Reached an EC50 of 591 ng/mL for population spike inhibition based on brain concentration, which closely matched the EC50 for target occupancy (545 ng/mL).
Caused dose-dependent decrease in wake-state EEG power across theta (4-10 Hz), alpha (10-15 Hz), and beta (15-30 Hz) bands; at 10 mg/kg, power was reduced to 81.2%, 70.6%, and 63.8% of vehicle control, respectively.
Induced a small, significant decrease in delta (1-4 Hz) power only at 1 mg/kg.
Caused significant, transient increase in locomotor activity for approximately 1 hour post-dose at 10 mg/kg.
Induced dose-dependent increase in latency to REM and NREM sleep.
Caused dose-dependent decreases in absolute EEG power during NREM and REM sleep.
Animal Model: albino CF1 (male)
Dosage: 0-40 mg/kg
Administration: p.o.; single dose
Result: Provided near-complete seizure protection at doses ≥5 mg/kg p.o.: 25/32 animals at these doses had Racine scores of 0, compared to 0/8 vehicle-treated animals.
Fitted an ED50 of 3.7 mg/kg p.o.
for seizure protection, with an EC50 of 938 ng/mL based on brain concentration.
Provided partial seizure protection: at doses ≥10 mg/kg p.o., 12/32 animals were protected in the 32 mA model, and 11/40 animals were protected in the 44 mA model.
Fitted an ED50 of 18.3 mg/kg p.o.
for the 32 mA model (76% maximum protection, EC50 4644 ng/mL plasma concentration) and 6.5 mg/kg p.o.
for the 44 mA model (22% maximum protection, EC50 2533 ng/mL plasma concentration).
Significantly increased the PTZ threshold for clonus from 33.3 mg/kg to 49.5 mg/kg.
Significantly increased the PTZ threshold for twitch from 30.7 g/kg to 42.4 mg/kg.
Protected 11/12 rats from seizure, compared to 1/12 rats protected with vehicle.
Significantly reduced mean afterdischarge duration from 92 seconds (vehicle) to 35 seconds.
性状 固体
颜色 White to off-white

化学信息

分子量 328.67
分子式 C14H8ClF3N2O2
CAS No. 2036081-86-2

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : ≥ 100 mg/mL (304.26 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.0426 mL15.2128 mL30.4257 mL76.0641 mL
5 mM0.6085 mL3.0426 mL6.0851 mL15.2128 mL
10 mM0.3043 mL1.5213 mL3.0426 mL7.6064 mL
15 mM0.2028 mL1.0142 mL2.0284 mL5.0709 mL
20 mM0.1521 mL0.7606 mL1.5213 mL3.8032 mL
25 mM0.1217 mL0.6085 mL1.2170 mL3.0426 mL
30 mM0.1014 mL0.5071 mL1.0142 mL2.5355 mL
40 mM0.0761 mL0.3803 mL0.7606 mL1.9016 mL
50 mM0.0609 mL0.3043 mL0.6085 mL1.5213 mL
60 mM0.0507 mL0.2535 mL0.5071 mL1.2677 mL
80 mM0.0380 mL0.1902 mL0.3803 mL0.9508 mL
100 mM0.0304 mL0.1521 mL0.3043 mL0.7606 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础